Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug--a key part of the pipeline--slashed HbA1c levels by 1.5% and 1.6%.
Sanofi is on track to resubmit its latest treatment for Type 2 diabetes after years of delay, as the drug came through on a long-term safety study designed to quell FDA concerns.
Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.
Connecticut biotech Biodel is touting midstage results for its long-acting insulin, as the in-development BIOD-531 better controlled glucose than two Eli Lilly therapies.
Sanofi has formed an alliance with medical device titan Medtronic to develop combo therapies that can improve patient adherence and simplify insulin treatment for the world's roughly 350 million sufferers of Type 2 diabetes.
Combine the blockbuster GLP-1 drug Victoza with a long-acting insulin and you get a treatment greater than the sum of its parts, according to Novo Nordisk, which unveiled promising new data on its diabetes cocktail IDegLira.
Eli Lilly will hardly be the first in the field of GLP-1 treatments for diabetes if and when it launches dulaglutide, but the company believes its drug has the data to stand out among its rivals and claim the lion's share of a multibillion-dollar market.
Isis says its lead diabetes drug scored a success in a Phase II study, with both doses of ISIS-GCGR spurring a significant drop in blood glucose levels after 13 weeks of therapy in a group of treatment-resistant patients. And the antisense therapy hit its marks on HbA1c without spurring some of the troubling side effects that may hinder rival therapies in the pipeline.
Two years after a stinging rejection at the hands of the same committee, Bristol-Myers Squibb and AstraZeneca got a warmer reception for their diabetes drug dapagliflozin, winning a recommendation from an FDA advisory panel and brightening their odds of approval for the once-rebuffed therapy.
AstraZeneca and Bristol-Myers Squibb are trying once again to get U.S. approval for their drug dapagliflozin, an innovative but potentially risky treatment for Type 2 diabetes.